Evidence map›Paper›PMID 35719969›Full record

ArticleFrontiers in oncology2022

A Novel Model Combining Tumor Length, Tumor Thickness, TNM_Stage, Nutritional Index, and Inflammatory Index Might Be Superior to the 8th TNM Staging Criteria in Predicting the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy.

Xiaohui Chen, Yilin Yu, Haishan Wu, Jianjian Qiu, Dongmei Ke, Yahua Wu, Mingqiang Lin, Tianxiu Liu, Qunhao Zheng, Hongying Zheng and 7 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiaohui ChenDepartment of Thoracic Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Yilin YuCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Haishan WuCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Jianjian QiuCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Dongmei KeCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Yahua WuCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Mingqiang LinCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Tianxiu LiuCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Qunhao ZhengCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Hongying ZhengCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Jun YangCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Zhiping WangCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Hui LiDepartment of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Lingyun LiuCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Qiwei YaoCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Jiancheng LiCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
Wenfang ChengCollege of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We aimed to determine whether the tumor length and tumor thickness should be used as prognostic factors for esophageal squamous cell carcinoma (ESCC) patients treated with definitive chemoradiotherapy (dCRT). Methods: A retrospective analysis consists of 902 non-operative ESCC patients received dCRT. The nomogram was used to predict the survival. Besides, Restricted Cubic Splines (RCS) was used to examine the relationship between prognostic factors and survival outcomes. Finally, the prognostic index (PI) scores were constructed according to the tumor length and tumor thickness, and the patients were divided into the low-, medium-, and high-risk groups. Results: The median follow-up of overall survival (OS) and progression-free survival (PFS) were 23.0 months and 17.5 months. Multivariate Cox regression analysis showed that tumor length and tumor thickness were independent prognostic factors associated with survival. Our novel nomograms for OS and PFS were superior to the TNM classification (p < 0.001). Besides, RCS analysis demonstrated that the death hazard of tumor length and tumor thickness sharply increased at 7.7 cm and 1.6 cm (p < 0.001). Finally, there were significant differences for ESCC patients with clinical TNM stage group of the OS and PFS in different risk groups. The higher risk group was significantly associated with shorter OS and PFS in ESCC patients (both p < 0.001 for all). Conclusion: The study results suggest that the novel models integrating tumor length and tumor thickness may provide a simple and widely available method for evaluating the prognosis of non-operative ESCC patients. The tumor length and tumor thickness should be considered as prognostic factors for ESCC.

Indexed as

esophageal squamous cell carcinomanovel prognostic modelprognostic index scoretumor lengthtumor thickness

Identifiers

PMID35719969
PMCPMC9198351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.